197 related articles for article (PubMed ID: 24128285)
1. Genetically engineered endostatin-lidamycin fusion proteins effectively inhibit tumor growth and metastasis.
Jiang WG; Lu XA; Shang BY; Fu Y; Zhang SH; Zhou D; Li L; Li Y; Luo Y; Zhen YS
BMC Cancer; 2013 Oct; 13():479. PubMed ID: 24128285
[TBL] [Abstract][Full Text] [Related]
2. An EGFR/CD13 bispecific fusion protein and its enediyne-energized analog show potent antitumor activity.
Sheng W; Shang Y; Li L; Zhen Y
Anticancer Drugs; 2014 Jan; 25(1):82-91. PubMed ID: 24100279
[TBL] [Abstract][Full Text] [Related]
3. Antitumor efficacy of the scFv-based fusion protein and its enediyne-energized analogue directed against epidermal growth factor receptor.
Sheng W; Shang Y; Miao Q; Li Y; Zhen Y
Anticancer Drugs; 2012 Apr; 23(4):406-16. PubMed ID: 22205154
[TBL] [Abstract][Full Text] [Related]
4. A bispecific enediyne-energized fusion protein containing ligand-based and antibody-based oligopeptides against epidermal growth factor receptor and human epidermal growth factor receptor 2 shows potent antitumor activity.
Guo XF; Zhu XF; Shang Y; Zhang SH; Zhen YS
Clin Cancer Res; 2010 Apr; 16(7):2085-94. PubMed ID: 20332319
[TBL] [Abstract][Full Text] [Related]
5. Tuftsin-based, EGFR-targeting fusion protein and its enediyne-energized analog show high antitumor efficacy associated with CD47 down-regulation.
Liu WJ; Liu XJ; Li L; Li Y; Zhang SH; Zhen YS
Cancer Immunol Immunother; 2014 Dec; 63(12):1261-72. PubMed ID: 25164878
[TBL] [Abstract][Full Text] [Related]
6. An EGFR/HER2-Bispecific and enediyne-energized fusion protein shows high efficacy against esophageal cancer.
Guo XF; Zhu XF; Yang WC; Zhang SH; Zhen YS
PLoS One; 2014; 9(3):e92986. PubMed ID: 24664246
[TBL] [Abstract][Full Text] [Related]
7. Enediyne-activated, EGFR-targeted human β-defensin 1 has therapeutic efficacy against non-small cell lung carcinoma.
Liu WJ; Zhu KL; Xu J; Wang JL; Zhu H
Lab Invest; 2018 Dec; 98(12):1538-1548. PubMed ID: 30206309
[TBL] [Abstract][Full Text] [Related]
8. A tandem scFv-based fusion protein and its enediyne-energized analogue show intensified therapeutic efficacy against lung carcinoma xenograft in athymic mice.
Zhong G; Zhang S; Li Y; Liu X; Gao R; Miao Q; Zhen Y
Cancer Lett; 2010 Sep; 295(1):124-33. PubMed ID: 20303650
[TBL] [Abstract][Full Text] [Related]
9. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
10. An enediyne-energized single-domain antibody-containing fusion protein shows potent antitumor activity.
Miao QF; Liu XY; Shang BY; Ouyang ZG; Zhen YS
Anticancer Drugs; 2007 Feb; 18(2):127-37. PubMed ID: 17159599
[TBL] [Abstract][Full Text] [Related]
11. Recombinant EGFR/MMP-2 bi-targeted fusion protein markedly binding to non-small-cell lung carcinoma and exerting potent therapeutic efficacy.
Xu J; Du Y; Liu XJ; Zhu BY; Zhang SH; Li L; Li Y; Wang XF; Shan CK; Wang RQ; Zhen YS
Pharmacol Res; 2017 Dec; 126():66-76. PubMed ID: 28392461
[TBL] [Abstract][Full Text] [Related]
12. Antitumor effects of an engineered and energized fusion protein consisting of an anti-CD20 scFv fragment and lidamycin.
Fang H; Miao Q; Zhang S; Cheng X; Xiong D; Zhen Y
Sci China Life Sci; 2011 Mar; 54(3):255-62. PubMed ID: 21416325
[TBL] [Abstract][Full Text] [Related]
13. Factor VII light chain-targeted lidamycin targets tissue factor-overexpressing tumor cells for cancer therapy.
Zhang Q; Liu XJ; Hu L; Liao DS; Zheng YB; Zhen YS; Song X
Int J Mol Med; 2012 Mar; 29(3):409-15. PubMed ID: 22108624
[TBL] [Abstract][Full Text] [Related]
14. A bispecific fusion protein and a bifunctional enediyne-energized fusion protein consisting of TRAIL, EGFR peptide ligand, and apoprotein of lidamycin against EGFR and DR4/5 show potent antitumor activity.
Zhu D; Wang X; Shang Y; Li Y; Jiang W; Li L; Chen SZ
Anticancer Drugs; 2015 Jan; 26(1):64-73. PubMed ID: 25122444
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activities of dFv-LDP-AE: An enediyne-energized fusion protein targeting tumor-associated antigen gelatinases.
Zhong GS; Wu MN; Guo XF; Zhang SH; Miao QF; Zhen YS
Oncol Rep; 2012 Oct; 28(4):1193-9. PubMed ID: 22797730
[TBL] [Abstract][Full Text] [Related]
16. MMP-2/9-oriented combinations enhance antitumor efficacy of EGFR/HER2-targeting fusion proteins and gemcitabine.
Qin Y; Liu XJ; Li L; Liu XJ; Li Y; Gao RJ; Shao RG; Zhen YS
Oncol Rep; 2014 Jul; 32(1):121-30. PubMed ID: 24807584
[TBL] [Abstract][Full Text] [Related]
17. An NGR-integrated and enediyne-energized apoprotein shows CD13-targeting antitumor activity.
Zheng YB; Shang BY; Li Y; Zhen YS
Biomed Pharmacother; 2013 Mar; 67(2):164-71. PubMed ID: 23206754
[TBL] [Abstract][Full Text] [Related]
18. A cell penetrating peptide-integrated and enediyne-energized fusion protein shows potent antitumor activity.
Ru Q; Shang BY; Miao QF; Li L; Wu SY; Gao RJ; Zhen YS
Eur J Pharm Sci; 2012 Nov; 47(4):781-9. PubMed ID: 22982402
[TBL] [Abstract][Full Text] [Related]
19. Generation and antitumor effects of an engineered and energized fusion protein VL-LDP-AE composed of single-domain antibody and lidamycin.
Miao Q; Shang B; Ouyang Z; Liu X; Zhen Y
Sci China C Life Sci; 2007 Aug; 50(4):447-56. PubMed ID: 17653664
[TBL] [Abstract][Full Text] [Related]
20. [Construction of energized fusion protein consisting of epidermal growth factor receptor oligopeptide ligand and lidamycin and its antitumor activity].
Guo XF; Zhong GS; Miao QF; Zhen YS
Ai Zheng; 2009 Jun; 28(6):561-8. PubMed ID: 19635191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
